



2Q13 EARNINGS



Contents

- ✚ **Financial Review**
- ✚ Operational Review
- ✚ A New Scope: Toiletries
- ✚ Ownership
- ✚ Appendices



Focused on Profitability...




(TRL in millions except EPS)


	As of June 30,		
	2013	2012	Chg
₺ Revenues	2,586.56	2,491.96	3.80%
Gross Income	209.02	236.99	-11.8%
Gross Margin	8.08%	9.51%	-1.43 pts
EBITDA	81.64	112.23	-27.25%
EBITDA Margin	3.16%	4.50%	-1.34 pts
Net Income	75.33	84.26	-10.60%
Net Income Margin	2.91%	3.38%	-0.47 pts
EPS	0.121	0.136	-11.03%

We have a track record of strong revenue growth...

₺



...that we have leveraged into higher income



Working Capital Management



₺ mn.	FY06	FY07	FY08	FY09	FY10	FY11	FY12	1Q13
A/R	1,209	1,303	1,502	1,538	1,538	1,538	1,571	1,661
Inventories	346	387	469	404	545	577	695	668
A/P	929	1,043	1,234	1,228	1,362	1,325	1,342	1,418
WC	626	647	737	714	721	790	924	911
WC/Sales (%)	19.88	17.83	18.21	14.20	14.70	15.57	18.84	18.23

OpEx Improvement



₺	FY06	FY07	FY08	FY09	FY10	FY11	FY12	2Q13
Revenue (mn.)	3,151	3,628	4,047	5,029	4,902	5,074	4,902	2,587
# of WHs	98	100	100	107	114	118	102	99
# of Employees	4,694	4,554	4,600	4,893	5,162	5,322	5,049	5,017
OpEx / Sales	4.84%	4.49%	4.57%	3.93%	4.28%	4.74%	5.37%	5.36%
Personnel / Sales	2.86%	2.69%	2.64%	2.39%	2.66%	2.79%	3.23%	3.09%
Employee per WH	48	46	46	46	45	45	50	50
Revenue per Employee	671,241	796,743	879,676	1,027,748	949,678	953,495	970,885	996,601

OpEx Breakdown



OPERATIONAL EXPENSES	20132Q	%	20122Q	%	2013 vs. 2012
Personnel expense	80,050,192	57.71%	76,696,083	57.29%	4.37%
Health sector fair expenses	9,546,056	6.88%	5,275,430	3.94%	80.95%
Fuel expense	10,646,120	7.68%	10,448,895	7.81%	1.89%
Transportation expense	6,822,777	4.92%	6,324,402	4.72%	7.88%
Depreciation expense	5,976,735	4.31%	5,659,874	4.23%	5.60%
Outsourced benefits and services	4,792,336	3.46%	6,188,802	4.62%	-22.56%
Other	3,805,421	2.74%	5,411,629	4.04%	-29.68%
Insurance expense	2,918,538	2.10%	2,258,039	1.69%	29.25%
Repair and maintenance expense of motor vehicles	2,808,022	2.02%	3,002,952	2.24%	-6.49%
Rent expense	2,747,140	1.98%	3,471,141	2.59%	-20.86%
Communication expense	2,377,395	1.71%	2,366,268	1.77%	0.47%
Tax expense	1,653,271	1.19%	1,056,522	0.79%	56.48%
Donations and aids	1,670,471	1.20%	2,630,177	1.96%	-36.49%
Stationery expense	1,210,383	0.87%	1,335,674	1.00%	-9.38%
Promotion expenses	465,820	0.34%	719,543	0.54%	-35.26%
Representation and host expenses	984,007	0.71%	794,541	0.59%	23.85%
Advisory and audit fees	230,485	0.17%	231,638	0.17%	-0.50%
Total	138,705,169		133,871,610		3.61%



Contents


- Financial Review
- Operational Review**
- A New Scope: Toiletries
- Ownership
- Appendices




Sustainable growth to Market Leader Position...



Market Share (%)




A progressive network across the Country by over 100 warehouses




	Main Warehouses	Regional Warehouses	Total
Selçuk Ecza	19	60	79
As Ecza	7	16	23
Group Total	26	76	102

Operational Stats I

Warehouses




Vehicle Fleet




Operational Stats II

Employment Size



Market Share (%)



Contents

- Financial Review
- Operational Review
- A New Scope: Toiletries**
- Ownership
- Appendices



Toiletry Segment: A significant catalyst...

✳ Selcuk Ecza has started to sell/distribute toiletry products (personal care products, cosmetics etc.) by June 1, 2009 and expanded it to all of its warehouses

✳ The market size in Turkey for toiletry products is approximately as of US\$11 bn. And almost US\$1 bn. of it is pharmacies' share



✳ Using the same distribution network, while by using the available spare capacity in warehouses lead to an insignificant increase in CAPEX

✳ Strategy to create a steady amount of additional revenue from this segment in order to support a sustainable profit level

✳ Higher gross margin around 10-11% compared to 7-8% from pharma segment




✳ Selcuk Ecza generated 265 mn. TRL in FY11 and 375 mn. in FY12 for this segment, while medium term target is 500 mn TRL as of app. 10% of available topline.

Contents

- Financial Review
- Operational Review
- A New Scope: Toiletries
- Ownership**
- Appendices



Ownership



Selcuk Ecza: A precious link to sustainable value creation



✦ **Attractive markets**

- ✦ Demographics drive long-term demand
- ✦ Public policy agenda supports greater access and improved efficiency

✦ **Well-positioned businesses**

- ✦ Solid operating profit and cash flow strength from distribution segment
- ✦ Nationwide network built over mutual commercial interests

✦ **Steady track record of delivering results and a balanced approach to capital deployment**

✦ **Strong balance sheet and solid liquidity position**

✦ **Experienced and tenured management team**

Contents

Appendices

- # Appendix-1: Reimbursement Schedule
- # Appendix-2: Reference Pricing Scheme
- # Appendix-3: The New Regulation
- # Appendix-4: Summary Financials:
Income Statement & Balance Sheet




REIMBURSEMENT to PHARMACIES by THE SSI



Appendix-2: Reference Pricing Scheme

Reference Countries

France
Italy
Spain
Portugal
Greece



100% = Brands Price (If its generic does not exist in the market)


60% = Brands Price (If its generic exists in the market)

60% = Generic Price

***The government has changed the regulation on the reference pricing mechanism and lowered the ratio of both brands and generics to 60% of the reference price on Nov.10, 2011 which is valid since Nov.18, 2011.**

REIMBURSEMENT

Generic Drugs in the Same Bioequivalence Group



**** The government recently lowered the price ceiling from 15% to 10% for the reimbursement price of generic drugs in the same bioequivalence group (which is applied over the lowest price of the generic product in the market; the lower 10% limit came into force from Nov. 5, 2011).**

Appendix-3: Major Regulatory Items as of Nov. 2011



- The price ceiling for **branded drugs** has been reduced to **60%** from 66% of the reference price, which is determined according to lowest price in the five reference EU member countries (France, Italy, Spain, Portugal, Greece), if the branded drug has a generic substitute available in the market, although the price ceiling remained at 100% for branded drugs that do not have generic substitutes.
- The price ceiling for **generics** has been also decreased from 66% to **60%** of the reference price.
- The drugs which stay on the market more than 20 years and with a wholesaler price higher than **TRL 6.79**, shall be priced at most **80%** of its reference price while their generics shall not be priced higher than their branded ones' wholesaler prices.
- All drugs with prices lower than **TRL3.56**, OTC drugs (without prescription), blood products, infant food, radiopharmaceutical products, enteral feeding products, and all other products that are not stated in public reimbursement list shall not be priced according to this new regulation.
- The exchange rate mechanism used to determine drug prices has also been changed. According to the new mechanism, the exchange rate may only be revised if the **90-day moving average of EUR/TRL exchange rate exceeds/falls** below the periodic EURO value band by **+/-5%**; while the upper end of this band is estimated as **10% higher** of the EUR/TRL exchange rate in effect for calculation of drug prices. (**The official EUR/TRL rate is 1.9595 since April 2009**)
- The Notice period for amending the “Reference Countries List” by the MoH has been reduced from 4 months to 2 months.

Appendix-4: Summary Financials: Income Statement-Consolidated

Income Statement


(TL Million)	Mar. 31, 2013	Mar. 31, 2012	2013 vs. 2012
Net Sales	2.586,56	2.491,96	3,80%
Cost of sales (-)	(2.377,55)	(2.254,97)	5,44%
GROSS PROFIT	209,02	236,99	-11,80%
OPEX	(138,71)	(135,27)	2,54%
Other operating income/Exp.(Net)	15,28	0,51	2912,69%
OPERATING PROFIT	85,59	102,23	-16,28%
Income/Expense from investment	37,82	7,78	386,26%
Finance income /Exp.(Net)	(28,84)	(5,19)	455,96%
EBIT	75,67	106,57	-29,00%
EBIT (exc.other)	70,31	101,72	-30,88%
Income before minority Int.& Tax	94,57	104,82	-9,78%
Minority interest	0,00	0,00	-16,97%
Income tax expense	(19,24)	(20,56)	-6,44%
Net Income / (Loss)	75,33	84,26	-10,60%
EBITDA	81,64	112,23	-27,25%
EBITDA (exc.other)	76,29	107,38	-28,96%
Gross Margin	8,08%	9,51%	
EBIT Margin	2,93%	4,28%	
EBIT Margin (exc.other)	2,72%	4,08%	
EBITDA Margin	3,16%	4,50%	

Appendix-4: Summary Financials: Balance Sheet



Balance Sheet

(TL million)					
Assets	June 30, 2013	Dec. 31, 2012	Liabilities & Equity	June 30, 2013	Dec. 31, 2012
Cash and cash equivalents	1,101.70	1,066.43	Short-term debt	918.97	895.53
Accounts rec.& due from related parties	1,660.83	1,570.86	Accounts payable & due to related parties	1,417.92	1,342.24
Inventories	667.70	695.13	Provisions & other current liabilities	40.66	39.17
Other current assets	97.17	63.60	Total Current Liabilities	2,377.55	2,276.93
Total Current Assets	3,527.40	3,396.01	Long-term debt	0.00	0.00
PP&E	180.40	168.77	Provision for Employee Benefits & Other Liabilities	12.7	10.20
Intangible Assets(Including Goodwill)	31.47	31.50	Deferred tax liability	15.43	20.52
Other non-current assets	15.13	15.34	Other liabilities	0.00	0.00
Deferred tax assets	18.94	22.05	Total Non-Current Liabilities	28.13	30.71
Total Non-Current Assets	245.94	237.66	Shareholder's equity & minority interest	1,367.66	1,326.02
Total Assets	3,773.34	3,633.67	Total Liabilities & Equity	3,773.34	3,633.67



2Q13 EARNINGS



Selcuk Ecza Deposu A.S.
Tel: +90 216 554 0554
Fax: +90 216 554 0517

Istanbul Stock Exchange: SELEC.IS
Bloomberg: SELEC.TI
Reuters: SELEC.IS

Investor Relations & Capital Markets
Tel: +90 216 554 0384-0385
www.selcukecza.com.tr
investorrelations@selcukecza.com.tr